Drug Type Small molecule drug |
Synonyms Fenofibrate/pitavastatin, HL-PIF, Livasupril + [4] |
Target |
Action inhibitors, agonists |
Mechanism HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors), PPARα agonists(Peroxisome proliferator-activated receptor α agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date South Korea (03 Apr 2019), |
Regulation- |
Molecular FormulaC25H24CaFNO4 |
InChIKeyAMUDYCAFPCQTAZ-NRFPMOEYSA-N |
CAS Registry147526-32-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Coronary Disease | South Korea | 30 Apr 2025 | |
Hyperlipidemias | South Korea | 03 Apr 2019 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Complex dyslipidemia | Phase 3 | - | 01 Nov 2015 |